Objective:
Discuss positive data from Oculis' phase 2 ACUITY trial of OCS-05 in acute optic neuritis and its implications for patients.
Key Findings:
- Privosegtor (OCS-05) achieved primary endpoint of cardiac safety with no significant difference from placebo.
- Lower MS relapse rates were observed in the OCS-05 group (10.5%) compared to steroid alone (35.7%).
- Efficacy endpoints showed preservation of retinal ganglion cell thickness and improved visual function.
Interpretation:
The positive results from the ACUITY trial indicate that OCS-05 may serve as a first-in-class neuroprotective treatment, addressing the unmet need for therapies that preserve neurons and axons in acute optic neuritis.
Limitations:
- The trial involved a small sample size of 36 patients.
- Further analysis and discussions with health authorities are needed before moving to registrational studies.
Conclusion:
The ACUITY trial results suggest broader applications for OCS-05 in neurodegenerative diseases, potentially benefiting patients in ophthalmology and neurology.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.